OOIR: Observatory of International Research

Papers

(The TQCC of JCO Precision Oncology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung Cancer	77
Sustained Response to the Mitogen-Activated Extracellular Kinase Inhibitor Trametinib in a Spindle Cell Sarcoma Harboring a QKI-RAF1 Gene Fusion	73
Role of Novel Bispecific Antibodies and Immunotherapy in Non–Small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations	65
Genomics of ERBB2-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab	65
Repotrectinib in a Patient With NTRK Fusion-Positive Pancreatic Carcinoma and Congenital Long QT Syndrome	64
Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care	64
Spontaneous and Treatment-Related Changes of Serum Calcitonin in Medullary Thyroid Cancer: Long-Term Experience in a Patient With Multiple Endocrine Neoplasia Type 2B	62
Targeted Therapies in Early-Stage Resectable Non–Small-Cell Lung Cancer: New Kids on the Block	55
Association of RNF43 Genetic Alterations With BRAF^V600E and MSI^high in Colorectal Cancer	53
CDK4/6 Inhibition With Anti–PD-1 Checkpoint Blockade Induces Major Response in Aggressive Classic Kaposi Sarcoma After Previous Progression on Anti-PD–1 Alone	49
Identification of a Suitable Subgroup for Radiation Dose Escalation in Definitive Concurrent Chemoradiation Therapy for Nonmetastatic Esophageal Squamous Cell Carcinoma	49
Precision Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine	48
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy	46
Incidental Diffuse Midline Glioma, H3 K27-Altered of the Pons Without Significant Coalterations	46
Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types	45
Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers	45
Identification and Validation of Gastric Adenocarcinoma Prognosis Features Based on Neutrophil-Related Genes	45
Understanding the Risk of Drug Interactions Between Ritonavir-Containing COVID-19 Therapies and Small-Molecule Kinase Inhibitors in Patients With Cancer	42
Parent Quality of Life After Disclosure of Pediatric Oncology Germline Sequencing Results	39
Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2–Amplified Metastatic Colorectal Cancer: Explora	37
Isolated MLH1 Loss by Immunohistochemistry Because of Benign Germline MLH1 Polymorphisms	35
Association Between Human Epidermal Growth Factor Receptor 2-Low Status and Time to Development of Brain Metastases Among Patients With Breast Cancer: A Retrospective Cohort Study	35
Comprehensive Review on the Clinical Impact of Next-Generation Sequencing Tests for the Management of Advanced Cancer	34
Larotrectinib Before Initial Radioactive Iodine Therapy in Pediatric TRK Fusion–Positive Papillary Thyroid Carcinoma: Time to Reconsider the Treatment Paradigm for Distantly Metastatic Disease?	34
Identification of Targetable EGFR Mutations in Ovarian Cancer	31

Acknowledgment of Reviewers, 2025	31
Prognostic Role of MTAP Loss in Cholangiocarcinoma	31
Comments on the Study of Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR -Mutant Lung Cancer	30
Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma	30
Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies	29
Reply to: Beyond the Score: Integrating Hypoxia Signatures Into Risk-Adapted Stereotactic Body Radiation Therapy for Early-Stage Non–Small Cell Lung Cancer	29
Targeted-Agent Continual Reassessment Method: A Novel Bayesian Enrichment Design for Phase I Trials of Molecularly Targeted Therapies	28
Reply to F. Dayyani et al	27
Clinical Impact and Genomic Features of Human Epidermal Growth Factor Receptor 2–Low Tumors in BRCA1/2 -Mutated Triple-Negative Breast Cancer	27
Targeted Next-Generation Sequencing in Succinate Dehydrogenase–Deficient GI Stromal Tumor Identifies Actionable Alterations in the PI3K/mTOR Pathway	27
Important Considerations for Real-World Analysis of Neurotrophic Tyrosine Receptor Kinase Fusion Cancer and Tropomyosin Receptor Kinase Inhibitors	26
Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia	26
Anti-KRAS G12C and Anti-EGFR Rechallenge in Chemotherapy-Refractory KRAS G12C–Mutated Colorectal Cancer: A Case Report	26
Reply to A. Rizzo et al	26
Detection of Copy-Number Variation in Circulating Cell-Free DNA in Patients With Uveal Melanoma	24
Prognostic Significance of Tumor-Infiltrating Lymphocytes Determined Using LinkNet on Colorectal Cancer Pathology Images	24
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for T	23
Impact of BRCA Mutation on Treatment Outcomes of Endocrine Therapy ± CDK4/6 Inhibitors in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor-2–Negative Bre	23
Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and MDM2 Amplification	22
A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2–Positi	21
Incorporating Continuous Mammographic Density Into the BOADICEA Breast Cancer Risk Prediction Model	21
Clinical Implication of HER2 Aberration in Patients With Metastatic Cancer Using Next-Generation Sequencing: A Pan-Tumor Analysis	21
Fatal Intracranial Hemorrhage With Belzutifan in von Hippel-Lindau Disease–Associated Hemangioblastoma: A Case Report	20
ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti–Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma	19
Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma	19
Genome-Scale Multimodal Analysis of Cell-Free DNA Whole-Methylome Sequencing for Noninvasive Esophageal Cancer Detection	19
Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types	19
Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I	19
Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape	19
Molecular Profiling of Biliary Tract Cancers in African American and Caucasian Patients	18
PD-L1 Expression in Biliary Tract Cancer: Comparison Across Antibody Clones and Role as a Predictor of Response to Chemoimmunotherapy: A Meta-Analysis	18
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors	18
Evaluating Patterns ofSDHxTumor Presentation by Gene and Variant Type: A Retrospective Analysis of a Large Clinical Cohort	18
Androgen Receptor Splice Variant 7 in Asian Patients With Metastatic Castration-Resistant Prostate Cancer	18
Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer	18
Implementation of DPYD and UGT1A1 Testing in Patients With GI Cancer: A Prospective, Nonrandomized Clinical Trial	18
EWSR1-PATZ1 Fusion Gene in Ependymoma: A Report of Two Adult Cases and Systematic Review of Literature	18
Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review	18
Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring anNTRKOncogenic Fusion	17
Computational Advancements in Cancer Combination Therapy Prediction	17
Unveiling the Origins of Pathogenic TP53 Variants in Clinical Context: A Molecular Tumor Board Case Discussion	17
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study	17
Mutation Spectrum in Liquid Versus Solid Biopsies From Patients With Advanced Gastroenteropancreatic Neuroendocrine Carcinoma	17
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial	16
Histology-Specific Prognostication for Radiation-Associated Soft Tissue Sarcoma	16
Practices and Views of US Oncologists and Genetic Counselors Regarding Patient Recontact After Variant Reclassification: Results of a Nationwide Survey	16
Phase II Study of Vismodegib in Patients With SMO- or PTCH1 -Mutated Tumors: Results From the National Cancer Institute Molecular Analysis	16
Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium	16
Pansarcoma Analysis of Cyclin-Dependent Kinase and Cyclin Outlier Gene Expression Highlights CDK7 as a Potential Therapeutic Target in Chordoma	16
Dissecting the Significance of Acid Phosphatase 1 Gene Alterations in Prostate Cancer	16

Intracranial Activity of Selpercatinib in Chinese Patients With AdvancedRETFusion–Positive Non–Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial	16
Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing	16
An Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry	16
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study	15
Gamma Secretase Inhibition for a Child With Metastatic Glomus Tumor and Activated NOTCH1	15
Assessment of Circulating Tumor DNA Burden in Patients With Metastatic Gastric Cancer Using Real-World Data	15
Predictive Model to Guide Brain Magnetic Resonance Imaging Surveillance in Patients With Metastatic Lung Cancer: Impact on Real-World Outcomes	15
Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors	15
Inflammatory Myofibroblastic Tumor With ROS1 Gene Fusions in Children and Young Adolescents	15
Circulating Lipid Profiles Associated With Resistance to Androgen Deprivation Therapy in Localized Prostate Cancer	15
Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma	15
A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma	15
Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer	14
Combination Therapy With Olaparib Plus Lenvatinib in a Patient With BRCA2 -Mutated, Radioiodine-Refractory, Metastatic Papillary Thyroid Cancer: A Case Report	14
Pan-Cancer Interrogation of MUTYH Variants Reveals Biallelic Inactivation and Defective Base Excision Repair Across a Spectrum of Solid Tumors	14
Using Dose-Escalation and -Expansion Cohort Study as Pivotal Trial for Targeted Anticancer Drug Approval	14
Erratum: Association of Baseline Tumor-Specific Neoantigens and CD8⁺ T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors	14
Adjuvant Chemotherapy in Premenopausal Patients With Hormone-Positive Breast Cancer With a Recurrence Score of 16-25: A Retrospective Analysis Using the National Cancer Database	14
Spontaneous Fluctuations of Tumor-Informed Circulating Tumor DNA at Low Levels	14
Unraveling Dexamethasone-Induced Neurobehavioral and Sleep Problems in Children With ALL: Which Determinants Are Important?	14
Development of a Composite Score Based on Carbohydrate Antigen 19-9 Dynamics to Predict Survival in Carbohydrate Antigen 19-9–Producing Patients With Pancreatic Ductal Adenocarcinoma After Neoadjuvant	14
Metastatic Colon Cancer Recurring After Cetuximab Plus Doublet Chemotherapy Harboring Acquired KRAS G12C Mutant that Responded to Sotorasib Plus Cetuximab	14
Erratum	14
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E	14
Analysis of Concordance Between Next-Generation Sequencing Assessment of Microsatellite Instability and Immunohistochemistry-Mismatch Repair From Solid Tumors	14
Mucin 16–Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes	14
Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid Cancers	14
MET/HGF Coexpression as a Novel Predictive Biomarker for Response to MET Inhibitor Therapy in a Case of Psammomatous Melanotic Schwannoma	14
Erratum: Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay	14
Assessing the Increased Variability in Individual Lesion Kinetics During Immunotherapy: Does It Exist, and Does It Matter?	13
Germline De Novo Mutations as a Cause of Childhood Cancer	13
Race-Associated Genomic Correlates of Therapeutic Response in African American Patients With Non–Small-Cell Lung Cancer	13
Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK Alterations	13
Spectrum and Clinical Impact of Secondary Genetic Alterations in Translocation-Associated Sarcomas	13
Prognostic Significance of Germline DICER1 Pathogenic or Likely Pathogenic Variants in Outcomes of Ovarian Sertoli-Leydig Cell Tumor	13
Urachal and Nonurachal Adenocarcinomas of the Urinary Bladder: A Comprehensive Genomic Profiling Study	13
DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes	13
Optimizing Access to Liquid Biopsy in the Present and Future Cancer Landscape	13
NF1-Driven Rhabdomyosarcoma Phenotypes: A Comparative Clinical and Molecular Study of NF1-Mutant Rhabdomyosarcoma and NF1-Associated Malignant Triton Tumor	13
Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer	13
Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing	13
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis	12
Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study	12
Role of Circulating Tumor DNA Tumor Fraction in Advanced Non–Small Cell Lung Cancer and Its Impact on Patient Treatment Outcomes: A Prospective Real-World Study	12
Social Genomics as a Framework for Understanding Health Disparities Among Adolescent and Young Adult Cancer Survivors: A Commentary	12
5-Hydroxymethylcytosine Profiling of Cell-Free DNA Identifies Bivalent Genes That Are Prognostic of Survival in High-Risk Neuroblastoma	12
Liposarcoma and Leiomyosarcoma as the First Manifestation of Familial Retinoblastoma: Implications for Genetic Testing and Carrier Surveillance	12
Vabametkib Treatment in Refractory Glioblastoma: A Case Report	12
Clinical Utility of Genomic Sequencing for Hereditary Cancer Syndromes: An Observational Cohort Study	12
Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non–Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival	12
Identification and Validation of Prognostic Model for Tumor Microenvironment-Associated Genes in Bladder Cancer Based on Single-Cell RNA Sequencing Data Sets	12
Erratum	12
Predictive Effectiveness of Circulating Tumor DNA in Recurrent Early-Stage Non–Small Cell Lung Cancer: An Updated Meta-Analysis	12
Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI Cancer	11
Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer	11
CNS Antitumor Activity of Amivantamab With Osimertinib in Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer With Acquired Mesenchymal-Epithelial Transition Amplification Resistance M	11
Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Carcinoma	11
Reply to S. Di Cosimo et al	11
Immune Checkpoint Inhibitors in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Resistant Chemotherapy-Naïve Advanced Non–Small Cell Lung Cancer: A Meta-Analysis Based on Eight Randomized T	11
Urban-Rural and Socioeconomic Differences in Patient Knowledge and Perceptions of Genomic Tumor Testing	11
Precision Treatment of Patients With GI Cancer Using Pre-emptive DPYD Genotyping/Phenotyping Plus Pharmacokinetic-Guided Dosing of 5-Fluorouracil	10
Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study	10
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases	10
Erratum: Reply to S. Di Cosimo et al	10
RET Alterations Differentiate Molecular Profile of Medullary Thyroid Cancer	10
Implementation of and Systems-Level Barriers to Guideline-Driven Germline Genetic Evaluation in the Care of Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia	10
Transcriptome-Based Prognostic and Predictive Biomarker Analysis of ENACT: A Randomized Controlled Trial of Enzalutamide in Men Undergoing Active Surveillance	10
Optimal Sequential Predictive Probability Designs for Early-Phase Oncology Expansion Cohorts	10
Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2	10
Remission of TP53 -Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD3	10
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose D	10
Toward Equitable Precision Oncology: Monitoring Racial and Ethnic Inclusion in Genomics and Clinical Trials	10
Transcriptomic Signatures Associated With Outcomes in Recurrent Prostate Cancer Treated With Salvage Radiation, Androgen-Deprivation Therapy, and Enzalutamide: Correlative Analysis of the STREAM Trial	10
Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy	10
Tracking the Response to Immunotherapy: Blood microRNA Dynamics in Patients With Advanced Non–Small Cell Lung Cancer	10
Real-World Outcomes of Molecular Tumor Board Treatment Recommendations	10
Outcome of Patients With Early-Stage Mismatch Repair Deficient Colorectal Cancer Receiving Neoadjuvant Immunotherapy: A Systematic Review	9
Characterization of the Tumor Microenvironment of De Novo Oligometastatic Breast Cancer in a Nationwide Cohort	9
Prognostic Value of the G2 Expression Signature and MYC Overexpression in Childhood High-Grade Osteosarcoma	9
Genetic Testing Utilization: Discrepancies Between Somatic and Germline Results in Patients With Cancer Reviewed at the UW Health Precision Medicine Molecular Tumor Board	9

Erratum: Precision-Guided Durable Response From Venetoclax With Decitabine in a Patient With a Metastatic Refractory IDH2 -Mutant Cholangiocarcinoma	9
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8 ⁺ and PD-1 ⁺ Cells Predict Superior Patien	9
Poly(ADP-Ribose) Polymerase Inhibitor Development: Promising Strategies to Move Beyond Approved Indications	9
Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study	9
Clinical Utility of a Circulating Tumor Cell–Based Cerebrospinal Fluid Assay in the Diagnosis and Molecular Analysis of Leptomeningeal Disease in Patients With Advanced Non–Small Cell Lung Cancer	9
MIR145 Core Promoter Methylation in Pretreatment Cell-Free DNA: A Liquid Biopsy Tool for Muscle-Invasive Bladder Cancer Treatment Outcome	9
Case of KRAS G12C-Mutated AML Treated With Sotorasib	9
Response to MEK Inhibitor Therapy inMAP2K1(MEK1) K57N Non–Small-Cell Lung Cancer and Genomic Landscape ofMAP2K1Mutations in Non–Small-Cell Lung Cancer	9
Utility of Tumor-Informed Circulating Tumor DNA for Monitoring Treatment Response in Nonmetastatic, Locally Advanced Penile and Primary Urethral Cancers	9
Erratum: Pharmacodynamic Activity of [ ¹⁸ F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With BRCA 1	9
Erratum	9
Optimizing Mainstreaming of Genetic Testing in Parallel With Ovarian and Endometrial Cancer Tumor Testing: How Do We Maximize Our Impact?	9
Incidental Pathogenic Variants in Renal Cell and Urothelial Carcinoma: Is It Time for Universal Screening?	9
Chemotherapy-Induced Peripheral Neuropathy and Falls in Cancer Survivors Relate to Digital Balance and Gait Impairments	9
Reply to: Comments on the Study of Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR -Mutant Lung Cancer	9
First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors	9
Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations	8
Modifiable Risk Factors and Risk of Colorectal and Endometrial Cancers in Lynch Syndrome: A Systematic Review and Meta-Analysis	8
Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase	8
Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy	8
A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression	8
Microsatellite Peak Shifts in Polymerase Chain Reaction-Based Fragment Length Data Correlate With Microsatellite Instability Degree and Vary With Mismatch Repair Gene Defects and Tumor Size	8
Abscopal Effect of Radiation on Liver Metastases of Poorly Differentiated Parotid Carcinoma	8
Transcriptional Profiling and Consensus Molecular Subtype Assignment to Understand Response and Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Colorectal Cancer	8
Elucidating Metastatic Organotropism in Renal Cell Carcinoma	8
Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial	8
ALK -Rearranged Non–Small Cell Lung Cancer Presenting as a Large Mediastinal Mass: A Case Report	8
Venetoclax and Azacitidine in the Treatment of NPM1-Mutated Donor Cell–Derived Leukemia in a Patient With Fanconi Anemia: Case Report and Literature Review	8
Prospective Clinical Validation of a Combinatorial Functional Precision Medicine Platform in Relapsed/Refractory Non-Hodgkin's Lymphoma	8
Mutant PPM1D- and TP53-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy	8
Erratum: Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRAS ^G12C -Mutated Non–Small Cell Lung Cancer: A Case Series	8
Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer	8
Cancer Risk Associated With PTEN Pathogenic Variants Identified Using Multigene Hereditary Cancer Panel Testing	8
Reducing Fluorouracil Doses in Patients With Partial Dihydropyrimidine Dehydrogenase Deficiency Is a Treatment Safety Strategy, Not a Panacea of Precision Dosing	8
Clinical Trial Diversity: A Bend in the Arc Toward Justice	8
Therapeutic Outcomes and Biomarker Potential of CDKL3 of Neoadjuvant Chemotherapy in Patients With Stage IIIC Versus Stage IV Epithelial Ovarian Cancer	8
Safety and Efficacy of Anti–Human Epidermal Growth Factor 2 Agents in the Treatment of Biliary Tract Cancers: A Systematic Review	8
Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers in the United States	8
Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers	7
Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis	7
Germline Pathogenic Variants in Patients With Pancreatic and Periampullary Cancers	7
Improving Access to Hereditary Testing in Pancreatic Ductal Carcinoma	7
Pan-Cancer Landscape of B- and T-Lymphocyte Attenuator: Implications for Potential Immunotherapy Combinations	7
Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor Genomics	7
Improved Cancer-Specific Risk Stratification by the Lymph Node Ratio-Based Nomogram: A Potential Role in Guiding Postoperative Management Decisions for Oral Cavity Carcinoma	7
Erratum: Case of a Patient With Pancreatic Cancer With Sporadic Microsatellite Instability Associated With a BRAF Fusion Achieving Excellent Response to Immunotherapy	7
Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors	7
Complete Response in Hairy Cell Leukemia to Anti-CD22 CAR T-Cell Therapy	7
Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer	7
Small Cell Transformation in a Patient With RET Fusion–Positive Lung Adenocarcinoma on Pralsetinib	7
DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance	7
Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel SNX8-BRAF Gene Fusion	7
Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function	7
Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care	7
Evaluation of Raw Cell-Free DNA Sequences for Gastric Cancer Detection	7
Prospective Study of Annual Whole-Body Magnetic Resonance Imaging as Part of a Multimodality Screening Program for Individuals With Li-Fraumeni Syndrome	7
Human Epidermal Growth Factor Receptor 2 Testing in Urothelial Carcinoma	7
Parents' Experiences With and Preferences for Receiving Information About Tumor Genomic Sequencing: Findings From a Qualitative Study and Implications for Practice	7
Skipping or Not Skipping? That's the Question! An Algorithm to Classify Novel MET Exon 14 Variants in Non–Small-Cell Lung Cancer	7
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols	7
Optimizing Radiotherapy Timing for Nasopharyngeal Carcinoma: The Impact of Radiation Scheduling on Survival	7
Real-World Analysis of Disparities in Biomarker Testing and Use of Recommended Targeted Therapies in Metastatic Non–Small Cell Lung Cancer in the United States	7
Genomic Risk Classifiers in Localized Prostate Cancer: Precise but Not Standardized	7
Response to BRAF and MEK Inhibitors in BRAF Thr599dup–Mutated Melanoma	7
Association of Pancreatic Adenocarcinoma Location With DNA Damage Response Status and Response to Platinum-Based Therapy	7
Clinical Response to Seribantumab, an Anti–Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an	7
Unleashing a Lazarus Effect With Selpercatinib in a Never-Smoker Patient With Stage IV, Chemo-Immunotherapy Refractory, RET C630Y-Mutant, Small-Cell Lung Cancer: A First Case Report	7
Genomic and Immune Landscape of Non–Small Cell Lung Cancer Brain Metastases	7
Risks and Implications of Multiple Actionable Pathogenic Germline Variants Discovered by Panel-Based Cancer Predisposition Testing	7
ESR1 Rearrangement as a Diagnostic and Predictive Biomarker in Uterine Tumor Resembling Ovarian Sex Cord Tumor: A Report of Four Cases	7
Framework for the Use of External Controls to Evaluate Treatment Outcomes in Precision Oncology Trials	7
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT	7
Fully Automated Artificial Intelligence Solution for Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Scoring in Breast Cancer: A Multireader Study	7
Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study	7
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer	7
Interpreting Nonrandomized Clinical Trial Data in Low-Grade Sarcoma: Differentiating Clinical Benefit From Indolent Disease Is Key	6
Reply to S. Chakrabarti and A. Mahipal	6
Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response	6
Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies	6
Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment	6
Disparate Rates of Germline Variants in Cancer Predisposition Genes in African American/Black Compared With Non-Hispanic White Individuals Between 2015 and 2022	6
Synthetic Lethal Co-Mutations in DNA Damage Response Pathways Predict Response to Immunotherapy in Pan-Cancer	6
Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion	6
B-Cell–Mediated Immunity Predicts Survival of Patients With Estrogen Receptor–Positive Breast Cancer	6
Lymphocyte Infiltration Score and Spatial Characteristics Refined the Prognosis and Denosumab Treatment Responsiveness Indicators for Giant Cell Tumor of Bone	6
Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U	6
Genomic Landscape of Malignant Phyllodes Tumors Identifies Subsets for Targeted Therapy	6
Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants	6
Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2–Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Orga	6
Neuroblastoma and Glioblastoma Cases With Amplified Oncogenes Have Reduced Numbers of Tumor-Resident Adaptive Immune Receptor Recombinations	6
Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges	6
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study	6
Exceptional Response to Dual Colony-Stimulating Factor 1 Receptor/PD-L1 Targeting After Primary Resistance to PD-1 Inhibition in a Patient With a Metastatic Uveal Melanoma	6
Mutational Features and Tumor Microenvironment Alterations in High-Grade Appendiceal Cancers Treated With Iterative Hyperthermic Intraperitoneal Chemotherapy	6
Mutation Burden Independently Predicts Survival in the Pan-Cancer Atlas	6